JNJ-28841072

JNJ-28841072 is a **novel, dual kinase inhibitor** that targets both **Aurora kinase** (particularly Aurora B) and the **vascular endothelial growth factor receptor (VEGFR)**. It suppresses phosphorylation of histone H3—inhibiting cell division—and disrupts tumor vascularization, leading to antiproliferative and anti-angiogenic effects. Developed as a potential treatment for hepatocellular carcinoma (HCC), JNJ-28841072 has shown preclinical efficacy by inducing cell polyploidy and death, and by reducing tumor growth and vessel formation in both in vitro cell cultures and mouse xenograft models. The compound is structurally optimized to interrupt the feedback loop between anti-angiogenesis-induced hypoxia and tumor aggressiveness by jointly blocking Aurora kinase and VEGFR pathways.